Goldman Sachs’s Inovio Pharmaceuticals INO Stock Holding History

Goldman Sachs’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-16,667	Closed	-$2.32M	–	5586
2020 Q3	$2.32M	Buy	+16,667	New	+$3.48M	﹤0.01%	3459
2016 Q1	–	Sell	-7,700	Closed	-$621K	–	7187
2015 Q4	$621K	Hold	7,700	–	–	﹤0.01%	4729
2015 Q3	$534K	Buy	+7,700	New	+$671K	﹤0.01%	5074
2015 Q1	–	Sell	-833	Closed	-$92K	–	7178
2014 Q4	$92K	Sell	833 -8,038	-91%	-$982K	﹤0.01%	6601
2014 Q3	$1.05M	Buy	8,871 +8,100	+1,051%	+$1.01M	﹤0.01%	4564
2014 Q2	$100K	Buy	+771	New	+$91K	﹤0.01%	6548

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's INO Position: Q2 2026 in Review

Goldman Sachs increased its Inovio Pharmaceuticals (INO) stake by 110% in Q2 2026, buying an estimated $58.1K and bringing the position to 93,720 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #6328.

Goldman Sachs first reported a position in INO in Q4 2013 and has held it in 50 quarters since. The position peaked at $14.4M in Q2 2020. 102 funds tracked by Wall St. Rank hold INO as of Q2 2026.

Goldman Sachs held 93,720 shares of Inovio Pharmaceuticals worth $103K as of Q2 2026.
Goldman Sachs bought 48,996 Inovio Pharmaceuticals shares in Q2 2026, an estimated $58.1K.
Inovio Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6328 holding.
Goldman Sachs first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
Goldman Sachs's Inovio Pharmaceuticals position peaked at $14.4M in Q2 2020.
102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.